[1]

Gradl G. 2023. Im Jahr 2022 wurden 72 % mehr orale Tumortherapeutika zulasten der GKV abgegeben als im Jahr 2013. www.dapi.de/aktuelles/zahl-des-monats/im-jahr-2022-wurden-72-mehr-orale-tumortherapeutika-zulasten-der-gkv-abgegeben-als-im-jahr-2013 (accessed on 21 October 2024)

[2]

Travi C, Würstlein R. 2021. Orale tumortherapie beim mammakarzinom. Pflegezeitschrift 74(6):50−53

doi: 10.1007/s41906-021-1043-5
[3]

Dong C, Wu J, Chen Y, Nie J, Chen C. 2021. Activation of PI3K/AKT/mTOR pathway causes drug resistance in breast cancer. Frontiers in Pharmacology 12:628690

doi: 10.3389/fphar.2021.628690
[4]

Heyn G. 2015. Orale Onkologika-besonderer Beratungsbedarf. Pharmazeutische Zeitung 160(35):2606−2611

[5]

Schlichtig K, Dürr P, Dörje F, Fromm MF. 2019. New oral anti-cancer drugs and medication safety. Deutsches Ä rzteblatt International. 116:775−782

doi: 10.3238/arztebl.2019.0775
[6]

Hirschberg L, Henze F, Paradies K, Winkler S, Schinköthe T, et al. 2025. Evaluation of therapy support through a standardized nursing consultation for patients undergoing oral tumor therapy in gynecological oncology within the prospective CAMPA initiative. European Journal of Oncology Nursing 74:102770

doi: 10.1016/j.ejon.2024.102770
[7]

Welslau M, Tesch H. 2022. OncoCoaching - eine patientenzentrierte versorgung in der onkologie. Im Fokus Onkologie 25(2):24−27

doi: 10.1007/s15015-022-3815-1
[8]

Zamora P, Riese C, Borges U, Baumann W, Schmitz S. 2014. Patientenkompetenz in der oralen krebstherapie (PACOCT). Forum 29(1):42−45

doi: 10.1007/s12312-013-1085-8
[9]

Shumilov E, Vehling-Kaiser U, Damnali G, Schulz X, Kaiser U, et al. 2022. Oral and subcutaneous anticancer therapy training course for non-physician healthcare professionals: a survey evaluating the relevance of its content and its implications in the practice of cancer care. Journal of Cancer Education 37(1):120−127

doi: 10.1007/s13187-020-01794-2
[10]

CANKADO. https://cankado.com (accessed on 5 October 2024)

[11]

LamaPoll. www.lamapoll.de (accessed on 5 October 2024)

[12]

Daikeler J, Bošnjak M, Lozar Manfreda K. 2020. Web versus other survey modes: an updated and extended meta-analysis comparing response rates. Journal of Survey Statistics and Methodology 8(3):513−539

doi: 10.1093/jssam/smz008
[13]

Hirschl N, Leveque W, Granitto J, Sammarco V, Fontillas M, et al. 2024. PARP inhibitors: strategic use and optimal management in ovarian cancer. Cancers 16(5):932

doi: 10.3390/cancers16050932
[14]

Henze F, Bornemann K, Haupt J, König A, Ortner P, et al. 2023. Interprofessionelles management der oralen tumortherapie. Im Fokus Onkologie 26(5):18−23

doi: 10.1007/s15015-023-3267-2
[15]

Harbeck N, Haupt J, Henze F, Koenig A, Lippach K, et al. 2022. Pflegeexpertinnen begleiten orale Tumortherapie. Die Schwester Der Pfleger 60(9):42−47

[16]

Sheer B, Wong FK. 2008. The development of advanced nursing practice globally. Journal of Nursing Scholarship 40(3):204−211

doi: 10.1111/j.1547-5069.2008.00242.x
[17]

Carnwell R, Daly WM. 2003. Advanced nursing practitioners in primary care settings: an exploration of the developing roles. Journal of Clinical Nursing 12(5):630−642

doi: 10.1046/j.1365-2702.2003.00787.x
[18]

Harbeck N, Fasching PA, Wuerstlein R, Degenhardt T, Lüftner D, et al. 2023. Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial. Annals of Oncology 34(8):660−669

doi: 10.1016/j.annonc.2023.05.003
[19]

Würstlein R, Wolff J, Harbeck N, Wülfing P. 2025. Digitale begleitung der therapie und nachsorge beim mammakarzinom. Die Onkologie 31:294−299

doi: 10.1007/s00761-024-01635-7